ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 79 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,420 | -46.5% | 11,309 | -31.4% | 0.00% | – |
| Q2 2023 | $127,885 | +1093.4% | 16,480 | +776.6% | 0.00% | – |
| Q1 2023 | $10,716 | +305.1% | 1,880 | +318.7% | 0.00% | – |
| Q4 2022 | $2,645 | +32.2% | 449 | +1.1% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 444 | -15.3% | 0.00% | – |
| Q2 2022 | $2,000 | -99.8% | 524 | -99.7% | 0.00% | – |
| Q1 2022 | $953,000 | -64.4% | 178,327 | -2.1% | 0.00% | -100.0% |
| Q4 2021 | $2,677,000 | -89.4% | 182,161 | -84.9% | 0.00% | -83.3% |
| Q3 2021 | $25,276,000 | +15.1% | 1,208,792 | -2.6% | 0.01% | +20.0% |
| Q2 2021 | $21,958,000 | -25.5% | 1,241,281 | +3.1% | 0.01% | -28.6% |
| Q1 2021 | $29,491,000 | +2.0% | 1,203,741 | +41.0% | 0.01% | 0.0% |
| Q4 2020 | $28,901,000 | +85.2% | 853,806 | +36.8% | 0.01% | +75.0% |
| Q3 2020 | $15,605,000 | -19.0% | 623,936 | +9.3% | 0.00% | -33.3% |
| Q2 2020 | $19,258,000 | – | 570,961 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |